000518.SHE Jiangsu Sihuan Bioengineering Co Ltd
- Market cap
- CNY 3.12B
- P/E
- -
- P/B
- 11.08x
- ROE
- -22.6%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000518.SHE undervalued?
Graham numberThe Graham number of Jiangsu Sihuan Bioengineering Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Sihuan Bioengineering Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Sihuan Bioengineering Co Ltd yet.
Jiangsu Sihuan Bioengineering Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow tr…
Full company profileJiangsu Sihuan Bioengineering Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Sihuan Bioengineering Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 327M | 346M | 396M | 418M | 505M | 351M | 270M | 235M | 204M | 344M | 312M |
| Gross Profit | 213M | 249M | 285M | 304M | 302M | 236M | 184M | 147M | 90.1M | 128M | 33.1M |
| Operating Income | -1.08M | 18.5M | -28.8M | 28.1M | 39.8M | -35.5M | -54.2M | -76.6M | -78.9M | -30.2M | -67.7M |
| EBITDA | 52.8M | 37.8M | -10.3M | 50.6M | 55.7M | -14.6M | -32.0M | -57.7M | -97.9M | -21.2M | -67.3M |
| Net Income | 4.47M | 7.29M | -29.4M | 14.3M | 27.3M | -34.8M | -48.8M | -75.3M | -110M | -37.1M | -64.7M |
| EPS | 0.00 | 0.01 | -0.03 | 0.01 | 0.03 | -0.03 | -0.05 | -0.07 | -0.11 | -0.04 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.02B | 932M | 926M | 916M | 824M | 799M | 738M | 661M | 567M | 494M | 710M |
| Total Liabilities | 406M | 256M | 283M | 256M | 139M | 153M | 145M | 148M | 168M | 135M | 379M |
| Shareholders' Equity | 611M | 629M | 599M | 614M | 641M | 606M | 557M | 482M | 372M | 335M | 286M |
| Cash & Short-term Investments | 64.9M | 40.7M | 39.4M | 53.1M | 54.6M | 38.3M | 28.3M | 19.1M | 8.18M | 89.6M | 85.8M |
| Total Debt | 53.0M | 50.0M | 70.0M | 16.0M | 16.0M | 51.1M | 48.7M | 42.5M | 30.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.6M | -10.8M | 22.6M | 58.6M | 100M | 156K | 4.87M | 1.63M | 1.46M | 78.1M | - |
| Capital Expenditure | 19.2M | 24.1M | 6.07M | 15.2M | 8.70M | 7.69M | 8.47M | 8.19M | 5.56M | 3.60M | 7.51M |
| Free Cash Flow | -7.62M | -34.9M | 16.5M | 43.4M | 91.5M | -7.53M | -3.61M | -6.56M | -4.10M | 74.5M | -39.8M |
| Ratios | |||||||||||
| ROE | 0.7% | 1.2% | -4.9% | 2.3% | 4.3% | -5.7% | -8.8% | -15.6% | -29.6% | -11.1% | -22.6% |
| ROA | 0.4% | 0.8% | -3.2% | 1.6% | 3.3% | -4.4% | -6.6% | -11.4% | -19.4% | -7.5% | -9.1% |
| Net Profit Margin | 1.4% | 2.1% | -7.4% | 3.4% | 5.4% | -9.9% | -18.1% | -32.0% | -54.0% | -10.8% | -20.7% |
| Debt to Equity | 0.09x | 0.08x | 0.12x | 0.03x | 0.02x | 0.08x | 0.09x | 0.09x | 0.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Sihuan Bioengineering Co Ltd dividends
- Dividend yield
- 0.02%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 26, 2003
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 575K | 0.00 | - |
| 2024 | CNY 600K | 0.00 | - |
| 2023 | CNY 766K | 0.00 | - |
| 2022 | CNY 717K | 0.00 | - |
| 2021 | CNY 704K | 0.00 | - |
| 2020 | CNY 541K | 0.00 | 2.0% |
| 2019 | CNY 3.50M | 0.00 | 24.4% |
| 2018 | CNY 2.70M | 0.00 | - |
| 2017 | CNY 11.8M | 0.01 | 161.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 26, 2003.
Who owns Jiangsu Sihuan Bioengineering Co Ltd
- Insiders 43.01%
- Institutions 0.00%
- Public & others 56.99%
- Shares outstanding 1.03B
- Free float 625M
Jiangsu Sihuan Bioengineering Co Ltd company profile
- Company name
- Jiangsu Sihuan Bioengineering Co Ltd
- Ticker
- 000518.SHE
- ISIN
- CNE0000001P8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 26, 1993
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 232
- Fiscal year end
- December
- Address
- No. 2 Binjiang East Road, Jiangyin, China, 214434
- Phone
- 86 510 8640 8558
- Website
- 000518shsw.com
About Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia; and Huanerbo, a human erythropoietin injection used to treat symptoms, such as anemia caused by renal insufficiency. It is also involved in the provision of flower planting; forest and natural ecosystem management and protection; forest improvement; forestry product sales; Chinese herbal medicine planting; landscaping project construction; urban municipal greening management; scenic area management; municipal facilities management; earthwork construction; engineering management services; forest park management and design management; external contracting; project cost consulting services; and sale of metal material, agricultural and sideline product, and building and decoration material. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
Jiangsu Sihuan Bioengineering Co Ltd management
5- Mr. Long ChenGM & Non-independent Director · born 1988
- Mr. Linfu WeiDeputy GM & Non-independent director · born 1988
- Mr. Yang ZhouDeputy GM & Board Secretary · born 1985
- Mr. Xiaofeng LiuDeputy General Manager · born 1965
- Ms. Haizhen XuAccounting Supervisor · born 1978